ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
124.305,57
-0,34%
S&P 500
5.304,72
0,70%
US Dollar vs BRL
5,1671
0,00%
Bitcoin
68.674,13
0,21%
Brent Oil
81,965
0,00%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Karyopharm Therapeutics Inc (KPTI)

  7. Karyopharm Therapeutics Inc (KPTI) Notícias

KPTI

Karyopharm Therapeutics (KPTI)

Karyopharm Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:KPTI
DataHoraFonteTítuloCódigoCompanhia
23/05/202417:30Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:KPTIKaryopharm Therapeutics Inc
14/05/202417:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KPTIKaryopharm Therapeutics Inc
08/05/202417:13Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KPTIKaryopharm Therapeutics Inc
08/05/202417:05PR Newswire (US)Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare ConferenceNASDAQ:KPTIKaryopharm Therapeutics Inc
08/05/202408:30PR Newswire (US)Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company ProgressNASDAQ:KPTIKaryopharm Therapeutics Inc
08/05/202408:30PR Newswire (US)Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029NASDAQ:KPTIKaryopharm Therapeutics Inc
07/05/202417:56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
02/05/202417:30PR Newswire (US)Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024NASDAQ:KPTIKaryopharm Therapeutics Inc
01/05/202417:05PR Newswire (US)Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KPTIKaryopharm Therapeutics Inc
24/04/202417:01PR Newswire (US)Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual MeetingNASDAQ:KPTIKaryopharm Therapeutics Inc
06/03/202418:05PR Newswire (US)Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma ConferencesNASDAQ:KPTIKaryopharm Therapeutics Inc
29/02/202409:43Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:KPTIKaryopharm Therapeutics Inc
29/02/202409:30PR Newswire (US)Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:KPTIKaryopharm Therapeutics Inc
22/02/202409:00PR Newswire (US)Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024NASDAQ:KPTIKaryopharm Therapeutics Inc
14/02/202412:33Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:KPTIKaryopharm Therapeutics Inc
08/01/202410:30PR Newswire (US)Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 ObjectivesNASDAQ:KPTIKaryopharm Therapeutics Inc
03/01/202409:00PR Newswire (US)Karyopharm to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:KPTIKaryopharm Therapeutics Inc
10/12/202322:15PR Newswire (US)Karyopharm Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Myelofibrosis Patients, with no SVR or TSS Progressions Observed As of the Data Cutoff(1)NASDAQ:KPTIKaryopharm Therapeutics Inc
08/11/202318:05PR Newswire (US)Karyopharm to Participate at Upcoming Investor ConferencesNASDAQ:KPTIKaryopharm Therapeutics Inc
06/11/202309:00PR Newswire (US)Karyopharm Announces New Preliminary Data in Overall Survival (OS) in Selinexor-Treated Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer as Part of Pre-Specified Exploratory Subgroup Analysis of the SIENDO StudyNASDAQ:KPTIKaryopharm Therapeutics Inc
02/11/202310:20PR Newswire (US)Karyopharm Announces Presentations at the 65th American Society of Hematology Annual Meeting and Exposition (ASH)NASDAQ:KPTIKaryopharm Therapeutics Inc
02/11/202308:30PR Newswire (US)Karyopharm Reports Third Quarter 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:KPTIKaryopharm Therapeutics Inc
30/10/202309:00PR Newswire (US)Karyopharm Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD™ Agent CC- 92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory Multiple MyelomaNASDAQ:KPTIKaryopharm Therapeutics Inc
26/10/202308:00PR Newswire (US)Karyopharm to Report Third Quarter 2023 Financial Results on November 2, 2023NASDAQ:KPTIKaryopharm Therapeutics Inc
26/09/202308:00PR Newswire (US)Karyopharm to Present Selinexor Data at the 2023 International Myeloma Society Annual Meeting and European Society of Gynaecological Oncology 2023 Annual MeetingsNASDAQ:KPTIKaryopharm Therapeutics Inc
01/09/202309:17Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
01/09/202309:00PR Newswire (US)Karyopharm Appoints Zhen Su, MD, MBA to its Board of DirectorsNASDAQ:KPTIKaryopharm Therapeutics Inc
02/08/202309:59Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:KPTIKaryopharm Therapeutics Inc
02/08/202308:30PR Newswire (US)Karyopharm Reports Second Quarter 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:KPTIKaryopharm Therapeutics Inc
26/07/202308:00PR Newswire (US)Karyopharm to Report Second Quarter 2023 Financial Results on August 2, 2023NASDAQ:KPTIKaryopharm Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:KPTI

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
PRIO3
PETRORIO ON
BOV
AMER3
Americanas ON
BOV
GOLL4
GOL PN
BOV
MGLU3
MAGAZINE LUIZA ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados